|
Characteristics
|
Total patients (n = 246)
|
Included patients (n = 180)
|
Included patients BMI ≤ 25 (n = 78)
|
Included patients BMI > 25 (n = 102)
|
|---|
|
Age (years)
|
47.6 ± 13.1
|
47.0 ± 12.7
|
42.9 ± 11.7
|
50.1 ± 12.6***
|
|
Male
|
146 (59)
|
107 (59)
|
39 (50)
|
68 (67)*
|
|
Disease duration (years)
|
10 (5–16)
|
8 (5–16)
|
7 (3–13)
|
9 (6–18)**
|
|
SpA subtype
|
|
Ankylosing spondylitis
|
179 (78)
|
140 (78)
|
64 (82)
|
76 (74)
|
|
Non-radiographic SpA
|
49 (22)
|
40 (22)
|
14 (18)
|
26 (26)
|
|
HLA-B27
|
174 (74)
|
131 (73)
|
61 (78)
|
70 (69)
|
|
Psoriasis/IBD/uveitis
|
71 (29)
|
58 (32)
|
27 (35)
|
31 (30)
|
|
Peripheral arthritis
|
97 (40)
|
86 (48)
|
38 (49)
|
48 (47)
|
|
BASDAI
|
5.8 ± 2.0
|
5.8 ± 2.0
|
5.5 ± 2.1
|
6.0 ± 1.9
|
|
ASDAS
|
3.3 ± 0.9
|
3.3 ± 1.0
|
3.2 ± 1.0
|
3.4 ± 1.0
|
|
ESR (mmHg)
|
17 (7–33)
|
17 (7–31)
|
19 (6–34)
|
16 (7–31)
|
|
CRP (mg/L)
|
5 (2–15)
|
6 (3–17)
|
7 (2–20)
|
5 (3–15)
|
|
Previous TNFi
|
43 (18)
|
35 (19)
|
13 (17)
|
22 (21)
|
|
TNFi type
|
|
Infliximab
|
107 (43)
|
74 (41)
|
25 (32)
|
49 (48)*
|
|
Adalimumab
|
139 (57)
|
106 (59)
|
53 (68)
|
53 (52)*
|
|
csDMARD
|
|
Any csDMARD
|
102 (42)
|
79 (44)
|
31 (40)
|
48 (47)
|
|
MTX
|
34 (15)
|
25 (14)
|
12 (15)
|
13 (13)
|
|
SSZ
|
46 (21)
|
36 (20)
|
10 (13)
|
26 (25)*
|
|
MTX and SSZ
|
22 (9)
|
18 (10)
|
9 (11)
|
9 (9)
|
|
Prednisone
|
22 (9)
|
20 (11)
|
11 (14)
|
9 (9)
|
- The table shows mean ± SD, median (IQR) or absolute number (percentage) for all patients included (n = 180). The results are also stratified by body mass index (BMI). p value < 0.05 was considered statistically significant. Significant statistical differences between the groups of included patients, stratified by BMI: *p < 0.05, **p < 0.01, ***p < 0.001. SpA spondyloarthritis, HLA-B27 human leucocyte antigen B27, ESR erythrocyte sedimentation rate, CRP C-reactive protein, IBD inflammatory bowel disease, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, ASDAS Ankylosing Spondylitis Disease Activity Index, TNFi tumour necrosis factor inhibitors, csDMARD conventional synthetic disease-modifying anti-rheumatic drug, MTX methotrexate, SSZ sulfasalazine
